ascendis transcon glp-1 program Pharma announced that the U.S. Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide, PTH,) injection as the First and Only treatment for adults with hyperparathyroidism. Palopegteriparatide is a prodrug GLP-1 Agonists: A Comprehensive Overview

Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC review topic of the week

For instance, limiting coverage to those with higher BMI levels could mean forfeiting rebates and increasing cost per person treated

Since discovering this scheme, Cincinnati CBP officers identified over 300 master carton smuggling attempts

[DOI] [PubMed] [Google Scholar] 57.Iwabuchi J, Koshimizu K, Nakagawa T

Fracture risk was lower in the GLP-1RA group when examining higher daily doses of the medications, when allowing follow-up to continue after medication change, and when examining hip fractures, specifically

10.1089/thy.2024.0387